Company news
Oruka Therapeutics, Inc. (NASDAQ:ORKA) news
Oruka Therapeutics, Inc. news releases on 6ix. Latest, Sep 23, 2026: Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing…
Press releases & updates
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
September 23, 2026
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
September 9, 2026
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
August 24, 2026
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
May 6, 2026
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
April 28, 2026
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
April 27, 2026
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
April 27, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
February 8, 2026
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
January 11, 2026
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Oruka Therapeutics Announces New Board Member and Board Transition
December 10, 2025
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 11, 2025
Oruka Therapeutics to Present at Multiple November Investor Conferences
October 28, 2025
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
September 16, 2025
Oruka Therapeutics Announces $180 Million Private Placement
September 16, 2025
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 10, 2025
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
July 20, 2025
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
June 30, 2025
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
May 20, 2025
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
May 19, 2025
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
April 28, 2025
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
March 6, 2025
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 5, 2025
Oruka Therapeutics to Present at Multiple March Investor Conferences
February 18, 2025
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
December 18, 2024
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
December 17, 2024
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
November 18, 2024
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
September 24, 2024
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 11, 2024
Oruka Therapeutics Announces $200 Million Private Placement
September 11, 2024
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
August 22, 2024
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
July 31, 2024
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 24, 2024
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
April 2, 2024
ARCA biopharma Announces 2023 Financial Results
January 31, 2024
ARCA biopharma Announces Third Quarter 2023 Financial Results
October 17, 2023
ARCA biopharma Announces Second Quarter 2023 Financial Results
July 20, 2023
ARCA biopharma Announces First Quarter 2023 Financial Results
April 23, 2023
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
February 23, 2023
ARCA biopharma Announces Third Quarter 2022 Financial Results
October 27, 2022
ARCA biopharma Announces Second Quarter 2022 Financial Results
August 1, 2022
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
June 20, 2022
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
May 4, 2022